Review

Published on 14 Jun 2023

T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets

in Vaccines and Molecular Therapeutics

Alexandre E. Nowill
Manuel Caruso
Pedro O. de Campos-Lima

Frontiers in Immunology

doi 10.3389/fimmu.2023.1133225

4,676 views
4 citations

Original Research

Published on 13 Jun 2023

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells

in Vaccines and Molecular Therapeutics

Alexandra Kegler
Laura Drewitz
Claudia Arndt
Cansu Daglar
Liliana Rodrigues Loureiro
Nicola Mitwasi
Christin Neuber
Karla Elizabeth González Soto
Tabea Bartsch
Larysa Baraban

Frontiers in Immunology

doi 10.3389/fimmu.2023.1204543

4,577 views
5 citations

Editorial

Published on 13 Jun 2023

Editorial: Current concepts of cellular and biological drugs to modulate regulatory T cell activity in the clinic, volume II

in Vaccines and Molecular Therapeutics

Valentin Wenger
Robert Zeiser

Frontiers in Immunology

doi 10.3389/fimmu.2023.1221904

1,309 views

Correction

Published on 12 Jun 2023

Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

in Vaccines and Molecular Therapeutics

Shanti Pather
Shabir A. Madhi
Benjamin J. Cowling
Paul Moss
Jeremy P. Kamil
Sandra Ciesek
Alexander Muik
Özlem Türeci

Frontiers in Immunology

doi 10.3389/fimmu.2023.1232965

1,051 views
5 citations

Original Research

Published on 12 Jun 2023

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

in Vaccines and Molecular Therapeutics

Chang Chu
Anne Schönbrunn
Dorothea Fischer
Yvonne Liu
Johann-Georg Hocher
Jutta Weinerth
Kristin Klemm
Volker von Baehr
Bernhard K. Krämer
Saban Elitok

Frontiers in Immunology

doi 10.3389/fimmu.2023.1187880

2,212 views
2 citations

Original Research

Published on 09 Jun 2023

Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection

in Vaccines and Molecular Therapeutics

Teresia W. Maina
Elizabeth A. Grego
Scott Broderick
Randy E. Sacco
Balaji Narasimhan
Jodi L. McGill

Frontiers in Immunology

doi 10.3389/fimmu.2023.1186184

6,272 views
1 citation

Original Research

Published on 09 Jun 2023

Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1

in Vaccines and Molecular Therapeutics

Mariana Gonzalez-Hernandez
Franziska Karola Kaiser
Imke Steffen
Malgorzata Ciurkiewicz
Geert van Amerongen
Ronen Tchelet
Mark Emalfarb
Markku Saloheimo
Marilyn G. Wiebe
Marika Vitikainen

Frontiers in Immunology

doi 10.3389/fimmu.2023.1204834

2,894 views

Original Research

Published on 08 Jun 2023

Protective RNA nanovaccines against Mycobacterium avium subspecies hominissuis

in Vaccines and Molecular Therapeutics

Bubacarr J.B. Touray
Mostafa Hanafy
Yashdeep Phanse
Rachel Hildebrand
Adel M. Talaat

Frontiers in Immunology

doi 10.3389/fimmu.2023.1188754

3,754 views
2 citations

Correction

Published on 07 Jun 2023

Corrigendum: Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine

in Vaccines and Molecular Therapeutics

Edgar Alonso Melgoza-González
Lorena Bustamante-Córdova
Jesús Hernández

Frontiers in Immunology

doi 10.3389/fimmu.2023.1188815

856 views

Original Research

Published on 05 Jun 2023

Analyzing the effect of the COVID-19 vaccine on Parkinson’s disease symptoms

in Vaccines and Molecular Therapeutics

Revati Sabat
Orrin L. Dayton
Amit Agarwal
Vinata Vedam-Mai

Frontiers in Immunology

doi 10.3389/fimmu.2023.1158364

23,210 views
3 citations

Brief Research Report

Published on 05 Jun 2023

Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform

in Vaccines and Molecular Therapeutics

Rajashree Patil
Sonali Palkar
Akhileshchandra Mishra
Rahul Patil
Vidya Arankalle

Frontiers in Immunology

doi 10.3389/fimmu.2023.1181991

2,077 views
3 citations

Methods

Published on 05 Jun 2023

Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactin

in Vaccines and Molecular Therapeutics

Vishal Rathod
Laxmikant Kadam
Manish Gautam
Prabhu Dasu Gumma
Kevin Marke
Cathy Asokanathan
Alex Douglas-Bardsley
Laura Hassell
Sachin Bhandare
Sumit Gupta

Frontiers in Immunology

doi 10.3389/fimmu.2023.1190404

4,680 views
5 citations

Review

Published on 02 Jun 2023

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement

in Vaccines and Molecular Therapeutics

Animesh Sarker
Nidhi Dhama
Rinkoo Devi Gupta

Frontiers in Immunology

doi 10.3389/fimmu.2023.1200195

16,540 views
20 citations

Review

Published on 02 Jun 2023

Virus tracking technologies and their applications in viral life cycle: research advances and future perspectives

in Vaccines and Molecular Therapeutics

Di Liu
Li Pan
Huanjie Zhai
Hua-Ji Qiu
Yuan Sun

Frontiers in Immunology

doi 10.3389/fimmu.2023.1204730

6,511 views
3 citations

Original Research

Published on 02 Jun 2023

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine

in Vaccines and Molecular Therapeutics

Yu-Min Choi
Dong Hyun Kim
Junghwa Jang
Bum-Joon Kim

Frontiers in Immunology

doi 10.3389/fimmu.2023.1155637

3,305 views
1 citation

Original Research

Published on 02 Jun 2023

Dectin-1 signaling coordinates innate and adaptive immunity for potent host defense against viral infection

in Vaccines and Molecular Therapeutics

Hyeong Won Kim
Mi-Kyeong Ko
So Hui Park
Seong Yun Hwang
Dong Hyeon Kim
Sun Young Park
Young-Joon Ko
Su-Mi Kim
Jong-Hyeon Park
Min Ja Lee

Frontiers in Immunology

doi 10.3389/fimmu.2023.1194502

3,031 views
5 citations

Navigation group

Articles

T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells

Editorial: Current concepts of cellular and biological drugs to modulate regulatory T cell activity in the clinic, volume II

Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection

Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1

Protective RNA nanovaccines against Mycobacterium avium subspecies hominissuis

Corrigendum: Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine

Analyzing the effect of the COVID-19 vaccine on Parkinson’s disease symptoms

Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform

Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactin

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement

Virus tracking technologies and their applications in viral life cycle: research advances and future perspectives

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine

Dectin-1 signaling coordinates innate and adaptive immunity for potent host defense against viral infection